NCT03233789 (EVA) is a clinical trial of neurologic rehabilitation in Neurologic Disorder, sponsored by Martin Brünger.

Who is sponsoring NCT03233789?

NCT03233789 is sponsored by Martin Brünger.

What drugs are being tested in NCT03233789?

Interventions in NCT03233789: neurologic rehabilitation.

What condition does NCT03233789 study?

NCT03233789 studies Neurologic Disorder, ICF, Medical Rehabilitation, Assessment, Functional Independence, Observational Study.

Is NCT03233789 still recruiting?

NCT03233789 is currently completed. Last updated 31 January 2019.

Last reviewed 2019-01-31 · How we verify

NCT03233789: EVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development and Validation of an ADL-score Based on FIM and EBI

Completed Last updated 31 January 2019

What this trial tests

trial testing neurologic rehabilitation in Neurologic Disorder in 265 participants. Completed in 31 December 2017.

Timeline

1 November 2015

Primary endpoint
24 February 2017

31 December 2017

Quick facts

Lead sponsor	Martin Brünger
Status	Completed
Study type	OBSERVATIONAL
Enrollment	265
Start date	1 November 2015
Primary completion	24 February 2017
Estimated completion	31 December 2017

Drugs / interventions tested

neurologic rehabilitation

Conditions studied

Neurologic Disorder — all drugs for Neurologic Disorder →
ICF — all drugs for ICF →
Medical Rehabilitation — all drugs for Medical Rehabilitation →
Assessment — all drugs for Assessment →

Sponsor

Martin Brünger

Who can join

18 and older, any sex, with Neurologic Disorder or ICF. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this mixed-methods-study is to develop and validate an algorithm to transform FIM (Functional Independence Measure) and EBI (Extended Barthel Index) into an ADL score (Activities of Daily Life) that can be used to compare outcome quality of rehabilitation clinics. The following steps are performed: 1. Development of an ADL-algorithms by experts 2. Validation of the ADL-algorithms in a quantitative approach 3. Finalization of the ADL-algorithms by experts based on study results

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neurologic Disorder

Currently open trials in the same condition.

NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT06208332 — The "What Is Important to Us" Communication Intervention Pilot Clinical Trial · Phase 2 · recruiting
NCT06750692 — Comparison of the Effects of Mirror Therapy,rTMS and Robotic-assisted Hand Therapy in Stroke Patients · NA · recruiting
NCT06883227 — Investigating Health Impacts of Exposure to Harmful Algal Blooms · recruiting
NCT06523270 — Advanced Imaging Holistic Omics Biobank · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03233789 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Martin Brünger
Last refreshed: 31 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03233789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing